January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases

January 10, 2022

$1,350M

$300M

n/a

n/a

up to $1,050M (dev., reg., and sales)

Undisclosed, per program

65%/35% (Pfizer/Beam) if co-dev and co-pro option is exercised

Beam’s proprietary in vivo base editing and LNP delivery technologies for the treatment of rare genetic diseases of the liver, muscle, and CNS

Option to License

Option to Co-Develop and Co-Promote with Shared Costs

• Beam signed a three year research partnership with Pfizer to co-develop in vivo base editing programs against three targets using its in vivo base editing and delivery technologies for the treatment of rare genetic diseases of the liver, muscle, and central nervous system with an exclusive, worldwide option to license each program.
• Beam may opt-in to global co-development and co-promotion for one licensed program; exercisable at the end of Phase 1/2 by paying an option exercise fee.
• Beam will receive $300M up front and is eligible to receive up to $1.05B in development, regulatory, and sales milestones, plus royalties per licensed program if not opted for co-development / co-promotion.
• If Beam opts in to co-dev/co-pro, both companies will share cost and profits 65%/35% (Pfizer/Beam).

Congrats to Beam and Pfizer for landing DealForma’s January 2022 Top Biopharma Deal. Last month’s Deal of the Month was Foghorn – Loxo using Gene Traffic Control for new oncology treatments. Read about it here.